Binaya Krushna Sahu
Sudipta Kumar Patra2
Mahesh Chandra Sahu- 1Centre for Biotechnology, Siksha ‘O’ Anusandhan (Deemed to be University), Kalinganagar, Bhubaneswar, Odisha, India
- 2Department of Orthopedics, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India
- 3Division of Microbiology, Indian Council of Medical Research (ICMR)-Regional Medical Research Centre, Chandrasekharpur, Bhubaneswar, Odisha, India
The rise of C. glabrata as a serious, multidrug-resistant organism poses a significant and global challenge to the human health. The reasons C. glabrata has developed resistance to standard antifungal drugs, include the activation of efflux pumps, the production of biofilms, and changes in ergosterol biosynthesis. In light of the threat posed by C. glabrata, the potential of phytochemicals as therapeutic alternatives should be considered due to their diverse structures and ability to exhibit more than one type of antifungal activity. This review summarizes advances in the use of plant-based natural products displaying antifungal activity against C. glabrata, with an emphasis on key classes of phytochemicals, including flavonoids, terpenoids, phenolic compounds, alkaloids, and essential oils. While the proposed mechanisms include disruption of cell membranes, inhibition of ergosterol synthesis, attenuation of oxidative stress, and suppression of virulence and biofilm formation, it is important to note that most evidence arises from in vitro studies, with only limited mechanistic investigations on individual compounds. Although in vitro studies indicate promising antifungal and adjunctive effects, the available evidence remains largely preclinical, with variable synergistic outcomes. Such synergy not only enhances therapeutic efficacy but also reduces required drug dosages, thereby minimizing toxicity and delaying the emergence of resistance. Major limitations include inconsistency in phytochemical composition, insufficient pharmacokinetic data, and a lack of robust in vivo and clinical studies. This review critically integrates current knowledge, highlighting both the multi-target potential of phytochemicals against C. glabrata and the key challenges that must be addressed to enable realistic clinical translation. By prioritizing synergy-focused research, and methodological standardization, phytocompounds can be positioned not merely as standalone agents but as adjunctive modulators of antifungal resistance, paving the way for novel, effective, and sustainable therapeutic options against MDR C. glabrata.
Introduction
Globally, invasive fungal infections pose a serious health issue, particularly for individuals who are hospitalized or immunocompromised. Candida species remain the most common cause of both superficial and systemic infections among fungal pathogens (Das et al., 2026). The epidemiology of candidemia has undergone significant changes over the past two decades. Previously, most cases were caused by Candida albicans, but non-albicans species, particularly C. glabrata (recently also known as Nakaseomyces glabratus), are now more frequently implicated (Katsipoulaki et al., 2024; Mallick et al., 2025; Sahu et al., 2025). Recent surveillance studies consistently report that C. glabrata accounts for approximately 13-30% of candidemia cases globally, with higher prevalence in hospital settings and high-risk patient populations, underscoring its growing clinical relevance (Jenkins, 2025; Dai et al., 2025; Yamin et al., 2025).
C. glabrata propensity for decreased sensitivity or complete resistance to traditional antifungal treatments increases its therapeutic importance. Fluconazole resistance rates commonly range from 2.6% to 10.6%, but can exceed 17% in certain regions, while echinocandin resistance, though generally low that has been increasingly reported in specific hospital settings (Won et al., 2021; https://www.cdc.gov/candidiasis/data-research/facts-stats/, https://www.cdc.gov/candidiasis/antimicrobial-resistance/index.html).
The prevalence of an increasing proportion of multidrug-resistant (MDR) C. glabrata is a serious public health issue due to the limited number of antifungal drug types and the high costs associated with treatment (Hassan et al., 2021). In fact, there is a significant global burden of invasive candidiasis: hundreds of thousands of cases of Candida bloodstream infection (BSI) are thought to occur each year, and these cases are frequently linked to high rates of morbidity and mortality (Rabault et al., 2025; Kotey et al., 2021; https://www.cdc.gov/candidiasis/antimicrobial-resistance/index.html).
These trends underscore the urgent need for innovative antifungal drugs with novel mechanisms of action, enhanced safety profiles, and a reduced propensity to induce resistance. In this context, plant-derived natural products, collectively referred to as phytochemicals, offer an attractive and underexplored reservoir of antimicrobial compounds. Many modern pharmaceuticals originate from natural products, and phytochemicals are characterized by structural diversity and the ability to target multiple fungal pathways simultaneously (Soliman et al., 2017; Dong et al., 2023).
Many classes of phytochemicals, such as flavonoids, terpenoids, alkaloids, phenolic acids, and components of essential oils, have been shown in recent reviews to exhibit potent antifungal activity against a variety of Candida species both in vitro and, in certain situations, in vivo (Esmaeili et al., 2025; Lu et al., 2017; Kerkoub et al., 2018; Kipanga et al., 2020). These natural substances have antifungal effects by interfering with virulence traits like biofilm formation and adhesion, disrupting fungal cell membranes, inhibiting ergosterol or other cell-wall or cell membrane biosynthesis pathways, inducing oxidative stress, and impairing efflux pump activity (Dantas et al., 2025; Khwaza and Aderibigbe, 2023; Esmaeili et al., 2025; El-Saadony et al., 2025; Panda et al., 2023; Soliman et al., 2017) (Table 1).
Table 1. Major classes of phytochemicals with demonstrated activity against Candida glabrata.
The increasing incidence of infections caused by non-albicans Candida species, including C. glabrata, particularly in light of their growing clinical importance and drug resistance patterns, highlights an urgent need to explore natural products for antifungal activity against these organisms. Much of the current research on antifungal natural products has thus far focused primarily on C. albicans (Dong et al., 2023; Calegari-Alves et al., 2025; Katsipoulaki et al., 2024) (Table 2). This review focuses specifically on plant-based compounds that can fight C. glabrata, a fungal pathogen that is often resistant to common antifungal drugs and less studied than other Candida species. It clearly explains how these natural compounds work, including their ability to reduce biofilms and their potential to enhance the effect of existing antifungal medicines. We aim to catalog key classes of phytochemicals with confirmed antifungal efficacy, critically identifying potential mechanisms through which they exert antifungal activity and evaluating available evidence for adjunctive or synergistic interactions between plant-derived preparations and known antifungal drugs, while also acknowledging current limitations and research gaps.
Table 2. Mechanisms of antifungal resistance in Candida glabrata and corresponding phytochemical interventions.
2 Biological characteristics of C. glabrata relevant to antifungal resistance
2.1 Genomic and physiological features
Phylogenetically and functionally, C. glabrata differs from the polymorphic C. albicans (Katsipoulaki et al., 2024). C. glabrata is a haploid organism, in contrast to the majority of pathogenic Candida species, and genome sequencing and comparative genomics place it significantly closer to the baker’s yeast Saccharomyces cerevisiae than to C. albicans (Roetzer et al., 2011; Enkler et al., 2016). The haploid genome enables the faster fixation of adaptive mutations under pharmacological selection and provides a genetic background that can more quickly reveal the phenotypic effects of single-nucleotide modifications (Roetzer et al., 2011; Hassan et al., 2021). C. glabrata and C. albicans differ physiologically in several therapeutically significant aspects that impact antifungal susceptibility, including diminished filamentation capacity. C. glabrata often only develops as budding yeast (blastoconidia), without the strong hyphae/pseudohyphae production characteristic of C. albicans. This “yeast-only” lifestyle alters host interaction and immune recognition, influencing dissemination strategies (Roetzer et al., 2011). High stress tolerance of C. glabrata exhibits pronounced tolerance to oxidative, nitrosative, and osmotic stresses encountered in the host (macrophage oxidative burst), mediated by a compact set of stress-response regulators (Kaloriti et al., 2012; Raj et al., 2024). This ability contributes indirectly to treatment failure and permits survival in challenging microenvironments. Strong adherence to host epithelia and abiotic surfaces is mediated by adhesins of the EPA (epithelial adhesin) family; many EPA genes are subtelomeric and variably expressed, allowing for quick phenotypic switching in adhesiveness (Timmermans et al., 2018; Fernández-Pereira et al., 2021). One of the primary factors influencing tolerance is adhesion, the initial stage of biofilm formation. Effective nutrient scavenging and metabolic adaptability, C. glabrata has developed effective absorption and utilization pathways that enable survival in biofilm environments and under nutrient constraint (Raj et al., 2024; Enkler et al., 2016). These physiological and genetic characteristics work together to produce a pathogen that is highly adaptive and stealthy, characteristics that promote persistence throughout antifungal therapy (Figure 1).
Figure 1. Biological features of Candida glabrata contributing to antifungal resistance and persistence. The figure summarizes key genetic, physiological, and virulence-associated traits that collectively enhance survival and multidrug resistance in C. glabrata. (1) The EPA (Epithelial Adhesin) family mediates strong adhesion to host tissues and abiotic surfaces, promoting robust biofilm initiation. (2) High stress tolerance enables survival under oxidative, osmotic, and other environmental stresses encountered during host infection and antifungal exposure. (3) Efficient nutrient scavenging and metabolic flexibility, including reliance on alternative carbon utilization pathways, support persistence under nutrient-limited conditions. (4) A yeast-only morphology contributes to stealthy immune evasion and a pathogenic strategy distinct from dimorphic Candida species. (5) Complex biofilm architecture, with an ECM, protects embedded cells, limits antifungal penetration, and supports long-term persistence. (6) The haploid genome facilitates rapid fixation of resistance-conferring mutations, accelerating adaptation to antifungal drugs. Together, these features reduce antifungal susceptibility and promote the development and maintenance of multidrug resistance in C. glabrata.
Importantly, these distinctive genomic and physiological traits also define critical therapeutic vulnerabilities. The reliance of C. glabrata on stress-response pathways, membrane plasticity, adhesion-mediated biofilm initiation, and metabolic flexibility provides multiple entry points for phytochemicals, which often exert multitarget effects rather than acting on a single molecular site. As discussed in later sections, several plant-derived compounds exploit these vulnerabilities by disrupting membrane integrity, impairing stress tolerance, and inhibiting adhesion and biofilm establishment, thereby counteracting the adaptive advantages conferred by these biological features.
2.2 Mechanisms of antifungal resistance
Resistance in C. glabrata is multifactorial and often arises during therapy. The main mechanisms implicated in clinical isolates are:
2.2.1 Efflux pump overexpression
Major facilitator superfamily (MFS) and ATP-binding cassette (ABC) transporters, particularly CgCDR1, CgCDR2, and CgSNQ2, are often overexpressed in clinical and experimental isolates. These transporters actively pump azoles and other compounds out of the cell, reducing intracellular drug concentrations (Sanguinetti et al., 2005; Torelli et al., 2008). Gain-of-function (GOF) mutations in the transcription factor PDR1, which up regulate several drug-resistance genes and have been frequently connected to the failure of fluconazole therapy, are frequently the cause of overexpression (Castanheira et al., 2022; Sanguinetti et al., 2005) (Figure 2).
Figure 2. The primary mechanisms that contribute to azole resistance in C. glabrata. Azole drugs target the ergosterol biosynthesis pathway by inhibiting 14-α-demethylase, disrupting fungal cell membrane formation. However, repeated exposure, overuse, and prophylactic treatment drive the development of azole resistance. C. glabrata employs several adaptive mechanisms to evade azole activity: (1) Overexpression of efflux pumps such as Cdr (ABC transporters) and Mdr (MFS transporters), which actively expel azole molecules from the cell; (2) Reduced azole import, limiting intracellular drug accumulation; (3) overproduction or functional alteration of sterol biosynthesis enzymes, including Erg3, Erg5, and Erg6, in addition to 14-α-demethylase (Erg11), which counteracts the inhibitory effect of azoles; and (4) Reduced azole affinity, caused by alterations in the drug target enzyme, preventing effective binding. Together, these mechanisms significantly reduce azole susceptibility and promote multidrug resistance in C. glabrata.
2.2.2 Alterations in ergosterol biosynthesis and membrane composition
Even though ERG11 mutations are less frequently the leading cause in C. glabrata than in C. albicans, changes in the genes involved in the ergosterol pathway and regulatory modifications that change the amount of sterol in the membrane have been noted and can either mediate cross-resistance to polyenes or decrease azole susceptibility (Vandeputte et al., 2012; Vu and Moye-Rowley, 2022; Memon et al., 2025). Crucially, sterol homeostasis and membrane composition may be indirectly impacted by PDR1-mediated alterations, exacerbating resistance mechanisms.
2.2.3 Echinocandin resistance via FKS mutations
β-1,3-glucan synthase is the target of echinocandins. The leading molecular cause of acquired echinocandin resistance in this species is point mutations in conserved “hotspot” regions of FKS1 and FKS2, which decrease drug binding and have been observed more frequently in clinical C. glabrata isolates, particularly following previous echinocandin exposure (Garcia-Effron et al., 2009; Katiyar et al., 2012; Zajac et al., 2025).
2.2.4 Biofilm-mediated tolerance
On catheters, prostheses, and mucosa, C. glabrata biofilms form dense communities embedded in an extracellular matrix (ECM) rich in extracellular DNA, proteins, and β-glucans. The matrix is responsible for creating a highly tolerant phenotype, which primarily occurs through the confinement of drugs within the matrix, thereby preventing the diffusion of drugs into the surrounding medium. Other factors contributing to high tolerance include differences in the expression of efflux pumps and stress response genes, as well as the presence of dormant (persister) cells within the matrix (Rodrigues et al., 2017; Gonçalves et al., 2021). Most importantly, fluconazole can be sequestered by the β-1,3-glucans of the matrix, which not only confers resistance to fluconazole but also provides matrix support for biofilm formation (Rodrigues et al., 2017).
Taken together, the resistance mechanisms of C. glabrata are not isolated adaptations but interconnected survival strategies that collectively promote multidrug resistance. These mechanisms increase fungal reliance on membrane integrity, stress-response pathways, metabolic flexibility, and biofilm architecture, thereby creating compensatory vulnerabilities. Importantly, many of these adaptations impose physiological costs that can be exploited therapeutically, particularly by agents capable of acting on multiple cellular targets simultaneously rather than a single molecular site.
Phytochemicals offer a mechanistically complementary approach to conventional antifungals. As detailed in the following sections, plant-derived compounds interfere with key resistance pathways by inhibiting efflux pumps, destabilizing membrane sterol composition, amplifying oxidative and cell wall stress, and dismantling biofilm structure (Table 3). Through these multitarget actions, phytochemicals can restore antifungal susceptibility, enhance drug penetration, and potentiate the activity of azoles and echinocandins against resistant C. glabrata. This integrated understanding of resistance biology provides the conceptual framework for evaluating phytochemical-based strategies as effective adjuncts or alternatives in the management of multidrug-resistant C. glabrata infections.
Table 3. Plant-derived compounds active against Candida glabrata.
3 Essential oil and phytochemicals with antifungal activity against C. glabrata
3.1 Essential oils
Essential oils (EOs) are volatile, aromatic secondary metabolites derived from various plant parts and are composed primarily of terpenoids, phenylpropanoids, and other low-molecular-weight compounds (Butnariu, 2021). Although EOs are frequently discussed as unified antifungal agents, their antifungal activity against C. glabrata is largely driven by a limited number of dominant constituents rather than the oil as a whole. The relative abundance and chemical nature of these major components, such as monoterpenes and aldehydes, largely determine antifungal potency, spectrum of activity, and toxicity (Bakkali et al., 2008).
The antifungal effects of EOs against C. glabrata primarily arise from membrane-active constituents, particularly carvacrol, thymol, and cinnamaldehyde, which readily partition into fungal lipid bilayers. These compounds increase membrane fluidity, disrupt ergosterol-dependent integrity, and cause leakage of intracellular ions, proteins, and nucleotides, leading to rapid fungistatic or fungicidal effects (Nazzaro et al., 2013; Tyagi and Malik, 2010). In addition, dominant EO constituents can induce intracellular reactive oxygen species (ROS) accumulation or impair fungal antioxidant defense systems, resulting in mitochondrial dysfunction and apoptosis-like cell death (Boukhatem et al., 2014).
Beyond membrane disruption, specific EO constituents interfere with biofilm-associated signaling pathways, including adhesion molecules and quorum-sensing systems, thereby inhibiting biofilm formation and destabilizing established biofilms. This effect is particularly relevant for C. glabrata, whose biofilm-associated drug tolerance contributes significantly to clinical treatment failure (Fernández-Calderón et al., 2021; Karpiński et al., 2023). Importantly, these anti-biofilm effects are not universal across all EOs but correlate strongly with the presence and concentration of key active molecules.
Among the most studied examples, oregano oil owes its antifungal efficacy primarily to carvacrol and thymol, which exhibit strong membrane-disruptive activity and significant synergy with azoles. Studies have shown that these constituents reduce fluconazole and itraconazole MICs and enhance antifungal susceptibility in azole-resistant C. glabrata isolates (Szweda et al., 2015; Fernandes et al., 2023; Váczi et al., 2024; Massa et al., 2018). Similarly, the antifungal activity of cinnamon oil is largely attributable to cinnamaldehyde, which inhibits ergosterol biosynthesis, suppresses efflux pump activity, and downregulates virulence-associated pathways, thereby restoring azole sensitivity in resistant strains (Shreaz et al., 2011; Saracino et al., 2022).
Despite promising in vitro and preclinical findings, the antifungal efficacy of EOs should not be generalized, as activity varies widely depending on chemical composition, extraction method, and constituent ratios. Moreover, the same membrane-active properties that damage fungal cells raise concerns regarding host cytotoxicity, including skin irritation, mucosal toxicity, and potential systemic effects at higher concentrations. Additional challenges, such as volatility, poor aqueous solubility, chemical instability, and batch-to-batch variability, complicate standardization, dosing, and clinical translation (Bakkali et al., 2008; Di Vito et al., 2023; Tyagi and Malik, 2010; Weisany et al., 2022; Wicaksono et al., 2020).
3.2 Flavonoids
Flavonoids are a broad class of polyphenolic phytochemicals widely distributed in vegetables, fruits, and medicinal plants. Although frequently discussed as a single group, antifungal activity among flavonoids is highly compound-dependent and should not be generalized across the class (Al Aboody and Mickymaray, 2020). At the cellular level, several flavonoids exert antifungal effects through membrane-targeting mechanisms, including increased membrane permeability, leakage of cytoplasmic contents, and destabilization of lipid organization. Flavonols such as quercetin and luteolin have been shown to disrupt fungal membrane integrity and permeability, resulting in loss of cell viability (Salazar-Aranda et al., 2015; Al Aboody and Mickymaray, 2020). Some flavonoids also inhibit ergosterol biosynthesis, leading to altered membrane composition and increased susceptibility to environmental and drug-induced stress (Dantas et al., 2025). In parallel, compounds such as quercetin and catechins can induce oxidative stress, overwhelming fungal antioxidant defenses and triggering apoptosis-like or necrotic cell death pathways (Stachelska et al., 2025; Tóth Hervay et al., 2024).
Quercetin is among the most consistently studied flavonoids against Candida spp. While much of the mechanistic work has been conducted in C. albicans, quercetin has demonstrated inhibitory activity against C. glabrata planktonic cells, with MICs comparable to fluconazole in some studies. Importantly, quercetin suppresses biofilm formation, downregulates virulence-associated genes, and enhances azole susceptibility, suggesting translational relevance for C. glabrata, which shares conserved efflux- and biofilm-associated resistance mechanisms (Salazar-Aranda et al., 2015; Schwarz et al., 2022).
Among catechins, epigallocatechin-3-gallate (EGCG) from green tea exhibits particularly strong intrinsic antifungal activity against C. glabrata. Under standardized EUCAST conditions, EGCG displayed a markedly lower MIC (0.3125 µg/mL) compared with fluconazole (4.0 µg/mL), and showed fungicidal effects at higher concentrations (Chen et al., 2015). These findings position EGCG as one of the most potent naturally occurring flavonoids against C. glabrata in vitro, although its clinical applicability is constrained by pharmacokinetic limitations.
Hesperetin has emerged as a notable antibiofilm agent. In clinical C. glabrata isolates, hesperetin eradicated mature biofilms at 2× MIC, achieving near-complete loss of viability within 24 hours, highlighting its potential relevance for biofilm-associated infections that are refractory to conventional antifungals (Sureendar et al., 2025).
Other flavonoids, including kaempferol, myricetin, luteolin, fisetin, and baicalein, show variable but measurable antifungal activity against C. glabrata, with MICs ranging from low single-digit µg/mL to values comparable with fluconazole (Salazar-Aranda et al., 2015). This variability reinforces the necessity of compound-level evaluation rather than class-wide extrapolation.
Beyond natural flavonoids, chalcone derivatives and semi-synthetic flavonoids demonstrate enhanced antifungal potency. Isoquercitrin exhibited consistent synergy with isavuconazole against resistant C. glabrata isolates (FICI 0.125–0.5) (Schwarz et al., 2022). Synthetic chalcone–triazole hybrids and benzofuran–indole chalcones inhibited C. glabrata growth at concentrations ≤50 µg/mL, while a brominated flavonoid derivative (BrCl-flav) outperformed fluconazole against resistant strains (Babii et al., 2021; Singampalli et al., 2025).
Despite strong in vitro efficacy, the clinical translation of flavonoids remains limited by poor aqueous solubility, low oral bioavailability, rapid metabolism, and restricted systemic exposure. Consequently, future work should prioritize drug delivery strategies, structural optimization, and in vivo pharmacokinetic studies to fully realize the therapeutic potential of compound-specific flavonoids against C. glabrata infections.
3.3 Terpenoids
Of all secondary metabolites produced by plants, terpenoids, including monoterpenes, sesquiterpenes, diterpenes, and triterpenoids, exhibit the greatest structural diversity (Ashour et al., 2010). Their pronounced hydrophobicity enables strong interactions with fungal cell membranes and intracellular targets, contributing to their antimicrobial potential (Huang et al., 2022). There is growing interest in terpenoids as antifungal or antifungal-adjuvant agents against C. glabrata, particularly due to their capacity to penetrate biofilms and circumvent resistance mechanisms such as efflux pump overexpression and alterations in ergosterol biosynthesis (Haque et al., 2016; Ivanov et al., 2022). Mechanistically, terpenoids exert antifungal effects through membrane disruption, interference with cell wall assembly, mitochondrial dysfunction, and modulation of oxidative stress pathways (Haque et al., 2016; Ivanov et al., 2022).
3.3.1 Highly active monoterpenes
Among terpenoids, phenolic monoterpenes exhibit the most potent and consistent antifungal activity against C. glabrata. Carvacrol and thymol are the best-characterized examples, demonstrating strong activity against both planktonic cells and biofilms. These compounds insert into the lipid bilayer, reducing membrane fluidity, increasing permeability, and causing leakage of ions and intracellular contents (Ahmad et al., 2011; Rao et al., 2010). This nonspecific membrane-disruptive mechanism is particularly advantageous against C. glabrata, whose resistance is often mediated by efflux pumps and ergosterol pathway alterations. Thymol additionally reduces ergosterol levels, while carvacrol inhibits fungal adhesion and disrupts established biofilms, frequently showing synergy with fluconazole (Ahmad et al., 2011; Kauser et al., 2024; Soulaimani et al., 2021; Balef et al., 2024).
Geraniol is another highly active monoterpene with robust antibiofilm efficacy against C. glabrata. Geraniol inhibits planktonic growth and eradicates mature biofilms by reducing extracellular matrix carbohydrates and eDNA, downregulating efflux pump (CDR1) and ergosterol biosynthesis genes, and inducing apoptosis-like cell death (Gupta and Poluri, 2021). Perillyl alcohol similarly disrupts biofilm biomass, perturbs ergosterol content, damages cell wall and membrane integrity, and enhances azole efficacy, allowing reduced antifungal dosing (Gupta and Poluri, 2021; Ansari et al., 2016).
Other active monoterpenes include eugenol and linalool, both of which exhibit measurable MIC and MFC values against clinical C. glabrata isolates. Eugenol and its synthetic glucoside derivatives display antifungal activity in the micromolar range while maintaining relative selectivity toward fungal cells over mammalian cells (De Souza et al., 2016; Didehdar et al., 2022). Linalool also shows synergistic effects with antifungal and antiseptic agents in checkerboard assays (Biernasiuk and Malm, 2023).
3.3.2 Weakly active terpenoids
In contrast, not all monoterpenes exhibit strong antifungal activity. Limonene, a non-phenolic monoterpene abundant in citrus essential oils, shows relatively weak and primarily fungistatic effects against Candida spp. While limonene can inhibit fungal growth at higher concentrations, it lacks potent fungicidal or antibiofilm activity compared with phenolic monoterpenes such as carvacrol, thymol, and geraniol (Ahmedi et al., 2024). These findings underscore that antifungal efficacy among terpenoids is structure-dependent and cannot be generalized across the class.
3.3.3 Triterpenoids
Beyond monoterpenes, triterpenoids such as ursolic acid and oleanolic acid represent a mechanistically distinct group with antifungal potential. Ursolic acid disrupts membrane integrity, inhibits efflux pumps, and induces oxidative stress in Candida species, including C. glabrata (Marena et al., 2021). Oleanolic acid, a structural analog, may inhibit ergosterol biosynthesis and reduce biofilm biomass (Tan et al., 2024). Although these compounds typically display higher MIC values than phenolic monoterpenes, their multitarget activity highlights their potential as lead scaffolds for antifungal development.
Essential oils rich in carvacrol or thymol, such as those from Origanum vulgare and Thymus vulgaris, demonstrate fungicidal activity against multiple Candida species, including C. glabrata. However, antifungal efficacy varies with chemical composition and strain origin, emphasizing the importance of attributing activity to specific constituents rather than essential oils as homogeneous mixtures (Cleff et al., 2010; Vahedi et al., 2016).
3.4 Phenolic compounds
Phenolic compounds represent a large and structurally diverse group of plant secondary metabolites, ranging from simple phenols and phenolic acids to complex polyphenols such as tannins (Crozier et al., 2006). Their chemical diversity enables interaction with multiple fungal targets, making phenolics attractive candidates for combating drug-resistant fungal pathogens, including C. glabrata. However, antifungal efficacy among phenolic compounds is highly compound-dependent and cannot be generalized across the class. Instead, differences in molecular complexity strongly influence potency, mechanism of action, and relevance for therapeutic development.
3.4.1 Simple phenols and phenolic acids
Simple phenolic compounds, including caffeic acid and gallic acid, exert antifungal activity primarily through protein denaturation and enzymatic inhibition, leading to disruption of essential metabolic pathways (Teodoro et al., 2015). These compounds interact directly with fungal proteins, impairing enzymatic catalysis and reducing cellular viability. In addition, simple phenolics disrupt mitochondrial function by interfering with the electron transport chain, resulting in ATP depletion, an effect that is particularly detrimental to C. glabrata, which relies heavily on metabolic plasticity for survival (Hassan et al., 2021; Salazar-Aranda et al., 2015; Alves et al., 2014).
Although phenolic acids are widely recognized as antioxidants in mammalian systems, their antifungal activity is predominantly associated with pro-oxidant effects within fungal cells. Gallic acid, in particular, induces intracellular ROS accumulation, disrupts redox homeostasis, and compromises mitochondrial integrity, ultimately leading to fungal cell death (Teodoro et al., 2015; Alves et al., 2014). Gallic acid has also been shown to increase membrane permeability, promote leakage of intracellular contents, reduce biofilm biomass, and enhance susceptibility to azoles, although its intrinsic antifungal potency is generally moderate and concentration-dependent.
3.4.2 Complex polyphenols
In contrast to simple phenolic acids, ellagic acid, a complex polyphenol abundant in pomegranates, berries, and nuts, exhibits broader and more targeted antifungal activity against C. glabrata. Ellagic acid acts through multiple resistance-relevant mechanisms, including inhibition of ergosterol biosynthesis and suppression of efflux pump activity, both of which are central to azole resistance in C. glabrata (Sampaio et al., 2021; Wicaksono et al., 2020). Importantly, ellagic acid has been shown to restore azole susceptibility in resistant C. glabrata isolates, positioning it as a promising antifungal adjuvant rather than a standalone agent.
Similar to gallic acid, the antifungal efficacy of ellagic acid is not attributable solely to antioxidant activity. Instead, its ability to induce redox imbalance, disrupt membrane integrity, and interfere with resistance-associated pathways underlies its antifungal action. The simultaneous targeting of membrane composition, efflux systems, and oxidative stress responses confers ellagic acid a higher functional relevance compared with simpler phenols.
3.4.3 Virulence and biofilm modulation
Beyond direct fungistatic or fungicidal effects, phenolic compounds can attenuate C. glabrata virulence by inhibiting adhesion, suppressing hydrolytic enzyme activity, and disrupting biofilm formation. Several phenolics downregulate genes involved in adhesion and extracellular matrix production, resulting in reduced biofilm biomass and increased susceptibility to antifungal therapy (Hassan et al., 2021; Rodrigues et al., 2017; Kumar and Kumar, 2023; Gupta et al., 2018; Duggan and Usher, 2023). These antivirulence effects are particularly relevant for C. glabrata, where biofilm-associated resistance contributes substantially to treatment failure.
3.5 Alkaloids
Alkaloids are chemically diverse nitrogen-containing secondary metabolites produced by numerous plant species, many of which have a long history of use in traditional medicine and documented antimicrobial activity (Thawabteh et al., 2024; Gupta et al., 2023). Although alkaloids are often discussed as a single antifungal class, their activity against C. glabrata is highly compound-specific and cannot be generalized. Only a limited number of alkaloids have been experimentally validated against C. glabrata, while many others lack sufficient activity or selectivity.
Among alkaloids, berberine is the most extensively characterized compound with confirmed antifungal relevance to C. glabrata. Berberine, isolated from Berberis, Coptis, and Hydrastis species, exhibits moderate intrinsic antifungal activity (reported MICs typically in the range of 64-256 µg/mL) but demonstrates pronounced synergistic effects with azole antifungals. Mechanistic studies have shown that berberine inhibits ABC efflux pumps, particularly Cdr1 through Pdr1-regulated pathways, disrupts mitochondrial function, and increases intracellular accumulation of fluconazole, leading to reversal of azole resistance in C. glabrata. Synergy with fluconazole has been confirmed in checkerboard assays, with reported fractional inhibitory concentration index (FICI) values ≤ 0.5, indicating true pharmacological synergy rather than additive effects (Dhamgaye et al., 2014; Gupta et al., 2023; Yong et al., 2020; Tong et al., 2021; Zheng et al., 2023).
Piperine, the principal alkaloid of Piper nigrum, exhibits limited standalone antifungal activity and should not be considered a primary antifungal agent. Instead, piperine functions predominantly as an adjuvant compound, enhancing antifungal efficacy through modulation of membrane dynamics, interference with drug efflux, and perturbation of fungal metabolism. While MIC/MFC values against C. glabrata are not consistently reported, available data suggest that piperine improves susceptibility to conventional antifungals rather than exerting strong fungicidal activity on its own.
Importantly, many plant-derived alkaloids frequently cited for antifungal properties, particularly those studied in C. albicans or other fungal species, have not been validated against C. glabrata. Current evidence supports antifungal relevance only for a small subset of alkaloids, with berberine representing the most robust example.
In addition to efficacy considerations, alkaloids warrant cautious evaluation due to host toxicity and drug–drug interaction risks. Several alkaloids induce dose-dependent adverse effects, including hepatotoxicity, neurotoxicity, cardiotoxicity, and cytotoxicity, largely through interactions with nucleic acids, mitochondrial function, and ion channels. Moreover, alkaloids can modulate drug-metabolizing enzymes and transporters, including cytochrome P450 isoenzymes (e.g., CYP3A4 and CYP2D6), UDP-glucuronosyltransferases, and P-glycoprotein, thereby altering the pharmacokinetics of co-administered drugs (Zhou, 2008). Berberine has been specifically reported to inhibit CYP3A4 and CYP2D6, raising the possibility of clinically relevant interactions when used alongside antifungals or other therapeutics (Gupta et al., 2023).
4 Synergistic interactions with conventional antifungals
A synergistic interaction of plant-based phytochemicals alongside traditional antifungal agents is becoming more prevalent in the treatment of MDR C. glabrata. This species is capable of overexpressing efflux pumps, forming biofilms, and developing resistance quickly. Therefore, many of the medications currently available, especially the azoles, are less effective. However, phytochemicals enhance susceptibility to antifungal agents via targeting different pathways, thus weakening fungal defenses and increasing the amount of drug delivered into the cell (De Andrade Monteiro and Ribeiro Alves Dos Santos, 2020). One of the most well-recognized mechanisms is efflux pump inhibition, as compounds such as quercetin and berberine have been shown to reduce the activity of ABC transporters like Cdr1 and Cdr2, restoring intracellular concentrations of fluconazole in resistant C. glabrata strains (Gupta et al., 2018; Ding et al., 2025). Membrane-active agents such as thymol, carvacrol, and several flavonoids disrupt the fungal plasma membrane, resulting in increased permeability to both azoles and polyenes (Kumar et al., 2019; Jadimurthy et al., 2023; Al Aboody and Mickymaray, 2020).
Another significant aspect of how synergism occurs includes modulation of the ergosterol pathway. Compounds that inhibit or decrease levels of ergosterol can improve binding of azoles to lanosterol 14α-demethylase (an enzyme targeted by azoles) and thus enhance the antifungal activity of azoles (Siswina et al., 2023). Additionally, many phytochemicals have been demonstrated to exhibit strong anti-biofilm effects. Cinnamaldehyde, EGCG, and apigenin can increase the susceptibility of C. glabrata biofilms to treatment with fluconazole and echinocandins due to their ability to disrupt components of the biofilm, such as the ECM and the adhesion of the fungal cells (Fydrych et al., 2025; Shariati et al., 2022; Bonincontro et al., 2023). These studies are important because biofilm-mediated antifungal tolerance is a significant obstacle to overcoming resistance to antifungal therapy in the clinical setting.
Despite these promising findings, a key limitation across the current literature is the absence of a standardized framework for assessing antifungal synergy. While checkerboard assays and time-kill studies are frequently employed, FICI values are not consistently reported, or different interpretive cut-offs are used, which hampers direct comparison between studies and limits translational relevance (De Andrade Monteiro and Ribeiro Alves Dos Santos, 2020). Standardized reporting of synergy metrics, including clearly defined FICI thresholds, strain backgrounds, and experimental conditions, is therefore essential to strengthen the rigor and reproducibility of phytochemical-antifungal combination studies.
Hopefully, the synergy created by combining phytochemicals with traditional antifungal drugs will help address C. glabrata’s MDR phenotype. The use of multiple physiologically active agents simultaneously, targeting various issues such as efflux, cell membrane integrity, stress response, and biofilm structure, should allow for restoration of the susceptibility of C. glabrata to antifungal drugs, enabling a decrease in the amount needed to treat, as well as potentially decreasing the risk of toxicity due to enhanced dosages of antifungal drugs. Continued studies in vitro, in vivo, and in the clinic are warranted, as the prevalence of drug resistance continues to rise worldwide, and the synergy achieved through these combinations of phytochemicals and antifungal drugs represents an exciting possibility for future therapeutic development.
5 Challenges and future perspectives
There have been numerous studies and advancements in identifying and researching the potential of phytochemicals as antifungal agents for C. glabrata; however, several barriers still prevent the use of these compounds in clinical settings. The primary barrier to clinical use is the variability in the composition of phytochemicals due to differences between plants, including but not limited to; species type; geographic location; the conditions under which the plant was grown; the extraction methods utilized; and the time at which it was harvested; all of these factors affect the presence/amount of, and the uniformity of, the bioactive compounds contained in the plant (Cowan, 1999; Scalbert et al., 2005). The inherent variability of phytochemical composition makes it increasingly challenging to achieve standardized products, batch-to-batch comparability, and regulatory approval for plant-derived antifungal therapies. To meet regulatory expectations for antifungal drug development, phytochemicals must undergo rigorous chemical characterization, including validated fingerprinting, identification of active constituents, and compliance with Good Manufacturing Practice standards. Without defined composition and reproducible bioactivity, advancement into preclinical and clinical development pipelines remains limited.
Even though many phytochemicals, such as phenolics, terpenoids, and alkaloids, exhibit strong in vitro activity, the overall lack of solid in vivo pharmacokinetic, pharmacodynamic, and toxicological data creates a significant obstacle to their advancement into the clinical development pipeline (Guevara-Lora et al., 2020; Didehdar et al., 2022). Additionally, there are currently very few clinical trials conducted for plant-derived antifungal agents, and no standardized methodologies exist to evaluate synergism, biofilm formation, or development of drug resistance, which has resulted in a lack of agreement between studies (Gupta and Poluri, 2021; Esmaeili et al., 2025). From a clinical development perspective, phytochemical-based antifungal strategies require a structured translational framework beginning with validated in vivo efficacy and toxicity studies, followed by phase I clinical trials assessing safety, tolerability, and pharmacokinetics. Subsequent phase II studies should focus on efficacy, particularly in combination with existing azoles or echinocandins, given the proposed role of phytochemicals as resistance-modifying or adjunctive agents in MDR C. glabrata infections. Interactions between antifungal medications and phytochemicals require thorough examination for potential synergism or antagonism with currently available antifungals, particularly with azole antifungals, and their subsequent impact on therapeutic outcomes (Soulaimani et al., 2021; Katragkou et al., 2015). Standardized methodologies for evaluating synergism, biofilm disruption, and resistance suppression should be prioritized to ensure cross-study comparability and regulatory acceptance of combination therapies.
Emerging research avenues will be necessary to address the challenges faced when developing phytochemicals against MDR C. glabrata. Advanced omics technologies, including transcriptomic, metabolomic, proteomic, and lipidomic approaches, can enhance understanding of the underlying mechanisms through which phytochemicals impact the action of efflux pumps, stress response pathways, virulence factors, and biofilm structure of C. glabrata (Silva et al., 2017; Rodrigues, 2018; Tits et al., 2020). Developing reliable chemical fingerprinting and extraction-standardization protocols will be essential for generating reproducible, quantifiable, and compliant (regulatory) phytochemical profiles for research and approval. Synergistic formulations combining phytochemicals with conventional antifungals represent a particularly promising strategy, as they may restore azole or echinocandin susceptibility, reduce required drug dosages, and limit the emergence of further resistance (Tits et al., 2020; Ansari et al., 2016; Nikoomanesh et al., 2023). Biological delivery systems made using nanotechnology, such as liposomes, nanoparticles, and nanoemulsions, offer exceptional solutions for enhancing: The effectiveness and stability of phytochemicals, along with the ability to improve targeted delivery of phytochemicals to deep tissue and the biofilm structure (Khoee and Madadi, 2023; De Almeida Campos et al., 2023). The incorporation of standardized in vivo models of mucosal, systemic, and biofilm-associated C. glabrata infections will be essential for bridging the gap between in vitro findings and clinical relevance, and for generating data suitable for regulatory submission (Hassan et al., 2021). Interdisciplinary collaboration amongst microbiologists, pharmacognosists, nanoscientists, chemists, and clinical researchers will be necessary to develop viable treatment options using phytochemicals for the treatment of MDR C. glabrata.
6 Conclusion
The increasing prevalence of MDR C. glabrata represents a significant challenge for current antifungal therapy and underscores the need for continued research into alternative and adjunctive treatment strategies. Phytochemicals encompass a diverse range of structural classes and exhibit multiple antifungal mechanisms, including disruption of fungal membranes, interference with ergosterol biosynthesis, modulation of oxidative stress, inhibition of drug efflux pumps, reduction of adhesion, and inhibition of biofilm formation. Among the most compelling strategies to overcome these barriers is the exploration of synergistic mechanisms between phytocompounds and conventional antifungals. Evidence suggests that phytochemicals such as phenolics, terpenoids, and alkaloids can potentiate the activity of azoles and echinocandins by modulating efflux pump activity, disrupting biofilm architecture, and attenuating virulence pathways. Such synergy not only enhances therapeutic efficacy but also reduces required drug dosages, thereby minimizing toxicity and delaying the emergence of resistance. Moreover, these interactions are variable and largely supported by in vitro studies, with effects broadly comparable to those reported for other Candida species. Significant challenges remain, including variability in phytochemical composition, limited pharmacokinetic and toxicological data, and the scarcity of well-designed in vivo and clinical studies. Future progress will depend on standardized extraction methods, mechanistic studies using systems biology approaches, and rigorous preclinical and clinical evaluation to determine whether phytochemical-based strategies can be reliably integrated into antifungal therapy for MDR C. glabrata.
Author contributions
BKS: Writing – original draft, Writing – review & editing. SKP: Conceptualization, Writing – original draft, Writing – review & editing. MCS: Conceptualization, Writing – original draft, Writing – review & editing. SKP: Conceptualization, Writing – original draft, Writing – review & editing.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Acknowledgments
This review is part of the Ph.D. research work of Mr. Binaya Krushna Sahu from the Centre for Biotechnology, Siksha ‘O’ Anusandhan (SOA) University. The authors express their sincere gratitude to the Dean of SOA University and the Director of ICMR-Regional Medical Research Centre (RMRC), Bhubaneswar, for their continued support and for providing the necessary facilities that enabled the successful completion of this review. The author SKP gratefully acknowledges the infrastructure facility provided by the president Prof. (Dr.) Manojranjan Nayak, Siksha ‘O’ Anusandhan (Deemed to be University), Bhubaneswar, India.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that Generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
ABC, ATP-binding cassette; ATP, Adenosine triphosphate; BSI, Bloodstream infection; CDR, Candida drug resistance (efflux pump proteins); ECM, Extracellular matrix; EGCG, Epigallocatechin-3-gallate; EOs, Essential oils; EPA, Epithelial adhesion; ERG, Ergosterol biosynthesis gene; EUCAST, European Committee on Antimicrobial Susceptibility Testing; FICI, Fractional inhibitory concentration index; FKS, β-1,3-glucan synthase gene; GOF, Gain-of-function; MAPK, Mitogen-activated protein kinase; MDR, Multidrug-resistant; MFS, Major facilitator superfamily; MIC, Minimum inhibitory concentration; MFC, Minimum fungicidal concentration; QS, Quorum sensing; ROS, Reactive oxygen species.
References
Ahmad A., Khan A., Akhtar F., Yousuf S., Xess I., Khan L. A., et al. (2011). Fungicidal activity of thymol and carvacrol by disrupting ergosterol biosynthesis and membrane integrity against Candida. Eur. J. Clin. Microbiol. Infect. Dis. 30, 41–50. doi: 10.1007/s10096-010-1050-8
Ahmedi S., Khan I., Ghanem S., and Manzoor N. (2024). Limonene synergistically augments fluconazole susceptibility in clinical Candida isolates from cleft lip and palate patients. Natl. J. Maxillofac. Surg. 15, 47–54. doi: 10.4103/njms.njms_34_23
Al Aboody M. S. and Mickymaray S. (2020). Anti-fungal efficacy and mechanisms of flavonoids. Antibiotics 9, 45. doi: 10.3390/antibiotics9020045
Alves C. T., Ferreira I. C., Barros L., Silva S., Azeredo J., and Henriques M. (2014). Antifungal activity of phenolic compounds identified in flowers from North Eastern Portugal against Candida species. Future Microbiol. 9, 139–146. doi: 10.2217/fmb.13.147
Ansari M. A., Fatima Z., and Hameed S. (2016). Anticandidal effect and mechanisms of monoterpenoid, perillyl alcohol against Candida albicans. PloS One 11, e0162465. doi: 10.1371/journal.pone.0162465
Ashour M., Wink M., and Gershenzon J. (2010). Biochemistry of terpenoids: monoterpenes, sesquiterpenes and diterpenes. Annu. Plant Rev. Vol. 40.: Biochem. Plant Sec. Metab., 258–303. doi: 10.1002/9781444320503.ch5
Babii C., Savu M., Motrescu I., Birsa L. M., Sarbu L. G., and Stefan M. (2021). The antibacterial synthetic flavonoid BrCl-Flav exhibits important anti-candida activity by damaging cell membrane integrity. Pharmaceuticals 14, 1130. doi: 10.3390/ph14111130
Bakkali F., Averbeck S., Averbeck D., and Idaomar M. (2008). Biological effects of essential oils–a review. Food Chem. Toxicol. 46, 446–475. doi: 10.1016/j.fct.2007.09.106
Balef S. S. H., Hosseini S. S., Asgari N., Sohrabi A., and Mortazavi N. (2024). The inhibitory effects of carvacrol, nystatin, and their combination on oral candidiasis isolates. BMC Res. Notes 17, 104. doi: 10.1186/s13104-024-06767-y
Biernasiuk A. and Malm A. (2023). Synergistic interactions between linalool and some antimycotic agents against Candida spp. as a basis for developing new antifungal preparations. Appl. Sci. 13, 5686. doi: 10.3390/app13095686
Bonincontro G., Scuderi S. A., Marino A., and Simonetti G. (2023). Synergistic Effect of Plant Compounds in Combination with Conventional Antimicrobials against Biofilm of Staphylococcus aureus, Pseudomonas aeruginosa, and Candida spp. Pharmaceuticals 16, 1531. doi: 10.3390/ph16111531
Boukhatem M. N., Ferhat M. A., Kameli A., Saidi F., and Kebir H. T. (2014). Lemon grass (Cymbopogon citratus) essential oil as a potent anti-inflammatory and antifungal drugs. Libyan. J. Med. 9. doi: 10.3402/ljm.v9.25431
Butnariu M. (2021). Plants as source of essential oils and perfumery applications. Bioprospect. Plant Biodivers. Ind. Molecules., 261–292. doi: 10.1002/9781119718017.ch13
Calegari-Alves Y. P., Costa R. P., Innocente-Alves C., do Nascimento Soares G., Lima E. S., Saciloto-de-Oliveira L. R., et al. (2025). A review of bioactive plant compounds against WHO priority fungal pathogens. Microb. Pathog. 207, 107930. doi: 10.1016/j.micpath.2025.107930
Castanheira M., Deshpande L. M., Davis A. P., Carvalhaes C. G., and Pfaller M. A. (2022). Azole resistance in Candida glabrata clinical isolates from global surveillance is associated with efflux overexpression. J. Global Antimicrob. Res. 29, 371–377. doi: 10.1016/j.jgar.2022.05.004
Chen M., Zhai L., and Arendrup M. C. (2015). In vitro activity of 23 tea extractions and epigallocatechin gallate against Candida species. Sabouraudia 53, 194–198. doi: 10.1093/mmy/myu073
Cleff M. B., Meinerz A. R., Xavier M., Schuch L. F., Meireles M. C. A., Rodrigues M. R. A., et al. (2010). In vitro activity of Origanum vulgare essential oil against Candida species. Braz. J. Microbiol. 41, 116–123. doi: 10.1590/S1517-83822010000100018
Cowan M. M. (1999). Plant products as antimicrobial agents. Clin. Microbiol. Rev. 12, 564–582. doi: 10.1128/CMR.12.4.564
Crozier A., Jaganath I. B., and Clifford M. N. (2006). Phenols, polyphenols and tannins: an overview. Plant Sec. Metabolites.: Occurr. Struct. Role. Hum. Diet. 1, 1–25.
Dai Z., Lan X., Cai M., Liao Y., Zhang J., Ye N., et al. (2025). Nineteen years retrospective analysis of epidemiology, antifungal resistance and a nomogram model for 30-day mortality in nosocomial candidemia patients. Front. Cell. Infect. Microbiol. 15, 1504866. doi: 10.3389/fcimb.2025.1504866
Dantas T. D. S., MaChado J. C. B., Ferreira M. R. A., and Soares L. A. L. (2025). Bioactive plant compounds as alternatives against antifungal resistance in the Candida strains. Pharmaceutics 17, 687. doi: 10.3390/pharmaceutics17060687
Das S., Mallick U., Sahu B., Turuk J., Sahu M. C., and Panda S. (2026). Clinical mycology: understanding pathogenesis, diagnosis, and antifungal strategies for invasive fungal infections: a review. Microbes Infect. Dis. 7, 713–734. doi: 10.21608/MID.2024.331599.2319
De Almeida Campos L., Fin M. T., Santos K. S., De Lima Gualque M. W., Freire Cabral A. K. L., Khalil N. M., et al. (2023). Nanotechnology-based approaches for voriconazole delivery applied to invasive fungal infections. Pharmaceutics 15, 266. doi: 10.3390/pharmaceutics15010266
De Andrade Monteiro C. and Ribeiro Alves Dos Santos J. (2020). “Phytochemicals and their antifungal potential against pathogenic yeasts,” in Phytochemicals in human health. (IntechOpen). doi: 10.5772/intechopen.87302
De Souza T. B., De Oliveira Brito K. M., Silva N. C., Rocha R. P., De Sousa G. F., Duarte L. P., et al. (2016). New eugenol glucoside-based derivative shows fungistatic and fungicidal activity against opportunistic Candida glabrata. Chem. Biol. Drug Des. 87, 83–90. doi: 10.1111/cbdd.12625
Dhamgaye S., Devaux F., Vandeputte P., Khandelwal N. K., Sanglard D., Mukhopadhyay G., et al. (2014). Molecular mechanisms of action of herbal antifungal alkaloid berberine, in Candida albicans. PloS One 9, e104554. doi: 10.1371/journal.pone.0104554
Didehdar M., Chegini Z., and Shariati A. (2022). Eugenol: A novel therapeutic agent for the inhibition of Candida species infection. Front. Pharmacol. 13, 872127. doi: 10.3389/fphar.2022.872127
Ding J., Yan Z., Peng L., Li J., Yang F., and Zheng D. (2025). Inhibitory effects of berberine on fungal growth, biofilm formation, virulence, and drug resistance as an antifungal drug and adjuvant with prospects for future applications. World J. Microbiol. Biotechnol. 41, 5. doi: 10.1007/s11274-024-04223-4
Di Vito M., Garzoli S., Rosato R., Mariotti M., Gervasoni J., Santucci L., et al. (2023). A new potential resource in the fight against Candida auris: the Cinnamomum zeylanicum essential oil in synergy with antifungal drug. Microbiol. Spectr. 11, e04385–e04322. doi: 10.1128/spectrum.04385-22
Dong F. R., Gao L., Wang L., Jiang Y. Y., and Jin Y. S. (2023). Natural products as antifungal agents against invasive fungi. Curr. Topics. Med. Chem. 23, 1859–1917. doi: 10.2174/1568026623666230417105227
Duggan S. and Usher J. (2023). Candida glabrata: A powerhouse of resistance. PloS Pathog. 19, e1011651. doi: 10.1371/journal.ppat.1011651
El-Saadony M. T., Saad A. M., Mohammed D. M., Korma S. A., Alshahrani M. Y., Ahmed A. E., et al. (2025). Medicinal plants: bioactive compounds, biological activities, combating multidrug-resistant microorganisms, and human health benefits-a comprehensive review. Front. Immunol. 16, 1491777. doi: 10.3389/fimmu.2025.1491777
Enkler L., Richer D., Marchand A. L., Ferrandon D., and Jossinet F. (2016). Genome engineering in the yeast pathogen Candida glabrata using the CRISPR-Cas9 system. Sci. Rep. 6, 35766. doi: 10.1038/srep35766
Esmaeili A., Saleh I., and Abu-Dieyeh M. H. (2025). Antifungal potential of plant-based extracts against Candida species: values, safety concerns, and possible applications. Phytochem. Rev. 24, 1–44. doi: 10.1007/s11101-025-10093-x
Essid R., Ayed A., Djebali K., Saad H., Srasra M., Othmani Y., et al. (2023). Anti-candida and anti-leishmanial activities of encapsulated Cinnamomum verum essential oil in chitosan nanoparticles. Molecules 28, 5681. doi: 10.3390/molecules28155681
Fernandes L., Costa R., Silva S., Henriques M., Costa-de-Oliveira S., and Rodrigues M. E. (2023). Effect of vapor-phase oregano essential oil on resistant Candida species biofilms: mechanisms of action. Microbiol. Spectr. 11, e05124–e05122. doi: 10.1128/spectrum.05124-22
Fernández-Calderón M. C., Hernández-González L., Gómez-Navia C., Blanco-Blanco M. T., Sánchez-Silos R., Lucio L., et al. (2021). Antifungal and anti-biofilm activity of a new Spanish extract of propolis against Candida glabrata. BMC Complement. Med. Ther. 21, 147. doi: 10.1186/s12906-021-03323-0
Fernández-Pereira J., Alvarado M., Gómez-Molero E., Dekker H. L., Blázquez-Muñoz M. T., Eraso E., et al. (2021). Characterization of Awp14, A novel cluster III Adhesin identified in a high biofilm-forming Candida glabrata isolate. Front. Cell. Infect. Microbiol. 11, 790465. doi: 10.3389/fcimb.2021.790465
Fydrych D., Jeziurska J., Wełna J., and Kwiecińska-Piróg J. (2025). Potential use of selected natural compounds with Anti-Biofilm activity. Int. J. Mol. Sci. 26, 607. doi: 10.3390/ijms26020607
Garcia-Effron G., Lee S., Park S., Cleary J. D., and Perlin D. S. (2009). Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1, 3-β-d-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53, 3690–3699. doi: 10.1128/AAC.00443-09
Gonçalves B., Azevedo N., Osório H., Henriques M., and Silva S. (2021). Revealing Candida glabrata biofilm matrix proteome: global characterization and pH response. Biochem. J. 478, 961–974. doi: 10.1042/BCJ20200844
Guevara-Lora I., Bras G., Karkowska-Kuleta J., González-González M., Ceballos K., Sidlo W., et al. (2020). Plant-derived substances in the fight against infections caused by Candida species. Int. J. Mol. Sci. 21, 6131. doi: 10.3390/ijms21176131
Gupta P., Gupta S., Sharma M., Kumar N., Pruthi V., and Poluri K. M. (2018). Effectiveness of phytoactive molecules on transcriptional expression, biofilm matrix, and cell wall components of Candida glabrata and its clinical isolates. ACS Omega. 3, 12201–12214. doi: 10.1021/acsomega.8b01856
Gupta P., Gupta H., Tripathi S., and Poluri K. M. (2023). Biochemical and metabolomic insights into antifungal mechanism of berberine against Candida glabrata. Appl. Microbiol. Biotechnol. 107, 6085–6102. doi: 10.1007/s00253-023-12714-x
Gupta P. and Poluri K. M. (2021). Elucidating the eradication mechanism of perillyl alcohol against Candida glabrata biofilms: insights into the synergistic effect with azole drugs. ACS Bio Med. Chem. Au. 2, 60–72. doi: 10.1021/acsbiomedchemau.1c00034
Haque E., Irfan S., Kamil M., Sheikh S., Hasan A., Ahmad A., et al. (2016). Terpenoids with antifungal activity trigger mitochondrial dysfunction in Saccharomyces cerevisiae. Microbiology 85, 436–443. doi: 10.1134/S0026261716040093
Hassan Y., Chew S. Y., and Than L. T. L. (2021). Candida glabrata: pathogenicity and resistance mechanisms for adaptation and survival. J. Fungi. 7, 667. doi: 10.3390/jof7080667
Hervay N. T., Elias D., Habova M., Jacko J., Morvova M. Jr., and Gbelska Y. (2023). Catechin potentiates the antifungal effect of miconazole in Candida glabrata. Folia Microbiol. 68, 835–842. doi: 10.1007/s12223-023-01061-z
Huang W., Wang Y., Tian W., Cui X., Tu P., Li J., et al. (2022). Biosynthesis investigations of terpenoid, alkaloid, and flavonoid antimicrobial agents derived from medicinal plants. Antibiotics 11, 1380. doi: 10.3390/antibiotics11101380
Ivanov M., Ćirić A., and Stojković D. (2022). Emerging antifungal targets and strategies. Int. J. Mol. Sci. 23, 2756. doi: 10.3390/ijms23052756
Jadimurthy R., Jagadish S., Nayak S. C., Kumar S., Mohan C. D., and Rangappa K. S. (2023). Phytochemicals as invaluable sources of potent antimicrobial agents to combat antibiotic resistance. Life 13, 948. doi: 10.3390/life13040948
Jenkins E. N. (2025). Population-based active surveillance for culture-confirmed candidemia—10 sites, United States 2017–2021. MMWR. Surveill. Summ. 74, 1–15.
Kaloriti D., Tillmann A., Cook E., Jacobsen M., You T., Lenardon M., et al. (2012). Combinatorial stresses kill pathogenic Candida species. Med. Mycol. 50, 699–709. doi: 10.3109/13693786.2012.672770
Karpiński T. M., Ożarowski M., Seremak-Mrozikiewicz A., and Wolski H. (2023). Anti-Candida and antibiofilm activity of selected Lamiaceae essential oils. Front. Biosci-Landmark. 28, 28. doi: 10.31083/j.fbl2802028
Katiyar S. K., Alastruey-Izquierdo A., Healey K. R., Johnson M. E., Perlin D. S., and Edlind T. D. (2012). Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. Antimicrob. Agents Chemother. 56, 6304–6309. doi: 10.1128/AAC.00813-12
Katragkou A., McCarthy M., Alexander E. L., Antachopoulos C., Meletiadis J., Jabra-Rizk M. A., et al. (2015). In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms. J. Antimicrob. Chemother. 70, 470–478. doi: 10.1093/jac/dku374
Katsipoulaki M., Stappers M. H., Malavia-Jones D., Brunke S., Hube B., and Gow N. A. (2024). Candida albicans and Candida glabrata: global priority pathogens. Microbiol. Mol. Biol. Rev. 88, e00021–e00023. doi: 10.1128/mmbr.00021-23
Kauser S., Raj N., Ahmedi S., and Manzoor N. (2024). Mechanistic insight into the membrane disrupting properties of thymol in Candida species. Microbe 2, 100045. doi: 10.1016/j.microb.2024.100045
Kerkoub N., Panda S. K., Yang M. R., Lu J. G., Jiang Z. H., Nasri H., et al. (2018). Bioassay-guided isolation of anti-Candida biofilm compounds from methanol extracts of the aerial parts of Salvia officinalis (Annaba, Algeria). Front. Pharmacol. 9, 1418. doi: 10.3389/fphar.2018.01418
Khoee S. and Madadi M. (2023). “Medicinal plant-based terpenoids in nanoparticles synthesis, characterization, and their applications,” in Secondary metabolites from medicinal plants (CRC Press), 53–86.
Khwaza V. and Aderibigbe B. A. (2023). Antifungal activities of natural products and their hybrid molecules. Pharmaceutics 15, 2673. doi: 10.3390/pharmaceutics15122673
Kipanga P. N., Liu M., Panda S. K., Mai A. H., Veryser C., Van Puyvelde L., et al. (2020). Biofilm inhibiting properties of compounds from the leaves of Warburgia ugandensis Sprague subsp ugandensis against Candida and staphylococcal biofilms. J. Ethnopharmacol. 248, 112352. doi: 10.1016/j.jep.2019.112352
Kotey F. C., Dayie N. T., Tetteh-Uarcoo P. B., and Donkor E. S. (2021). Candida bloodstream infections: changes in epidemiology and increase in drug resistance. Infect. Dis.: Res. Treat 14, 11786337211026927. doi: 10.1177/11786337211026927
Kumar A., Khan F., and Saikia D. (2019). Exploration of medicinal plants as sources of novel anticandidal drugs. Curr. Topics. Med. Chem. 19, 2579–2592. doi: 10.2174/1568026619666191025155856
Kumar D. and Kumar A. (2023). Cellular attributes of Candida albicans biofilm-associated in resistance against multidrug and host immune system. Microb. Drug Res. 29, 423–437. doi: 10.1089/mdr.2022.0347
Li Z. J., Guo X., Dawuti G., and Aibai S. (2015). Antifungal activity of ellagic acid in vitro and in vivo. Phytother. Res. 29, 1019–1025. doi: 10.1002/ptr.5340
Lu M., Li T., Wan J., Li X., Yuan L., and Sun S. (2017). Antifungal effects of phytocompounds on Candida species alone and in combination with fluconazole. Int. J. Antimicrob. Agents 49, 125–136. doi: 10.1016/j.ijantimicag.2016.10.021
Mallick U., Sahu B. K., Hegde R., Jena P., Turuk J., Sahu M. C., et al. (2025). Antifungal resistance in vaginal candidiasis among reproductive-age women: A review. Curr. Pharm. Biotechnol. doi: 10.2174/0113892010368329250503175104
Marena G. D., Fonseca-Santos B., Matheus Aparecido dos Santos R., dos Santos K. C., Bauab T. M., and Chorilli M. (2021). Incorporation of ursolic acid in liquid crystalline systems improves the antifungal activity against Candida sp. J. Pharm. Innovation 16, 576–586. doi: 10.1007/s12247-020-09470-0
Massa N., Cantamessa S., Novello G., Ranzato E., Martinotti S., Pavan M., et al. (2018). Antifungal activity of essential oils against azole-resistant and azole-susceptible vaginal Candida glabrata strains. Can. J. Microbiol. 64, 647–663. doi: 10.1139/cjm-2018-0082
Memon S., Ghanchi N. K., Zafar U., Farooqi J., Zaka S., and Jabeen K. (2025). Detection of ERG11 gene mutation in coding and non-coding regions of clinical Candida glabrata (Nakaseomyces glabratus) isolates from Pakistan. Access Microbiol. 7, 000952–0009v6. doi: 10.1099/acmi.0.000952.v6
Nazzaro F., Fratianni F., De Martino L., Coppola R., and De Feo V. (2013). Effect of essential oils on pathogenic bacteria. Pharmaceuticals 6, 1451–1474. doi: 10.3390/ph6121451
Nikoomanesh F., Falahatinejad M., Černáková L., Dos Santos A. L. S., Mohammadi S. R., Rafiee M., et al. (2023). Combination of farnesol with common antifungal drugs: inhibitory effect against Candida species isolated from women with RVVC. Medicina 59, 743. doi: 10.3390/medicina59040743
Panda S. K., Khan A., Swain S. S., Aissa A., Mukazayire M. J., Van Puyvelde L., et al. (2023). The anticandidal activity of the diterpenediol 8 (14), 15-sandaracopimaradiene-7alpha, 18-diol from Tetradenia riparia against the emerging pathogen Candida auris. Phytother. Res. 37, 3–6. doi: 10.1002/ptr.7638
Park B. J., Park J. C., Taguchi H., Fukushima K., Hyon S. H., and Takatori K. (2006). Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts. Biochem. Biophys. Res. Commun. 347, 401–405. doi: 10.1016/j.bbrc.2006.06.037
Rabault C., Shuping L., Mpembe R., Quan V., Lanternier F., Lortholary O., et al. (2025). Recent systemic antifungal exposure and nonsusceptible candida in hospitalized patients, South Africa 2012–2017. Emerg. Infect. Dis. 31, 1901. doi: 10.3201/eid3110.250359
Raj K., Paul D., Rishi P., Shukla G., Dhotre D., and YogeshSouche (2024). Decoding the role of oxidative stress resistance and alternative carbon substrate assimilation in the mature biofilm growth mode of Candida glabrata. BMC Microbiol. 24, 128. doi: 10.1186/s12866-024-03274-9
Rao A., Zhang Y., Muend S., and Rao R. (2010). Mechanism of antifungal activity of terpenoid phenols resembles calcium stress and inhibition of the TOR pathway. Antimicrob. Agents Chemother. 54, 5062–5069. doi: 10.1128/AAC.01050-10
Rodrigues C. F. (2018). Candida glabrata biofilms: mechanisms of antifungal resistance and matrix role (Portugal: Universidade do Minho).
Rodrigues C. F., Rodrigues M. E., Silva S., and Henriques M. (2017). Candida glabrata biofilms: how far have we come? J. Fungi. 3, 11. doi: 10.3390/jof3010011
Roetzer A., Gabaldón T., and Schüller C. (2011). From Saccharomyces cerevisiae to Candida glabrata in a few easy steps: important adaptations for an opportunistic pathogen. FEMS Microbiol. Lett. 314, 1–9. doi: 10.1111/j.1574-6968.2010.02102.x
Sahu B. K., Mallick U., Hegde R., Turuk J., Sahu M. C., and Panda S. K. (2025). Genetic diversity and antifungal resistance in Candida albicans from VVC cases in Indian women. BMC Microbiol. 25, 535. doi: 10.1186/s12866-025-04256-1
Salazar-Aranda R., Granados-Guzmán G., Pérez-Meseguer J., González G. M., and Waksman de Torres N. (2015). Activity of polyphenolic compounds against Candida glabrata. Molecules 20, 17903–17912. doi: 10.3390/molecules201017903
Sampaio A. D. G., Gontijo A. V. L., Lima G. D. M. G., de Oliveira M. A. C., Lepesqueur L. S. S., and Koga-Ito C. Y. (2021). Ellagic acid–cyclodextrin complexes for the treatment of oral candidiasis. Molecules 26, 505. doi: 10.3390/molecules26020505
Sanguinetti M., Posteraro B., Fiori B., Ranno S., Torelli R., and Fadda G. (2005). Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob. Agents Chemother. 49, 668–679. doi: 10.1128/AAC.49.2.668-679.2005
Saracino I. M., Foschi C., Pavoni M., Spigarelli R., Valerii M. C., and Spisni E. (2022). Antifungal activity of natural compounds vs. Candida spp.: a mixture of cinnamaldehyde and eugenol shows promising in vitro results. Antibiotics 11, 73. doi: 10.3390/antibiotics11010073
Scalbert A., Johnson I. T., and Saltmarsh M. (2005). Polyphenols: antioxidants and beyond. Am. J. Clin. Nutr. 81, 215S–217S. doi: 10.1093/ajcn/81.1.215S
Schwarz P. V., Nikolskiy I., Dannaoui E., Sommer F., Bange G., and Schwarz P. (2022). Synergistic in vitro interaction of Isavuconazole and Isoquercitrin against Candida glabrata. J. Fungi. 8, 525. doi: 10.3390/jof8050525
Shariati A., Didehdar M., Razavi S., Heidary M., Soroush F., and Chegini Z. (2022). Natural compounds: a hopeful promise as an antibiofilm agent against Candida species. Front. Pharmacol. 13, 917787. doi: 10.3389/fphar.2022.917787
Shreaz S., Bhatia R., Khan N., Muralidhar S., Basir S. F., Manzoor N., et al. (2011). Spice oil cinnamaldehyde exhibits potent anticandidal activity against fluconazole resistant clinical isolates. Fitoterapia 82, 1012–1020. doi: 10.1016/j.fitote.2011.06.004
Silva S., Rodrigues C. F., Araújo D., Rodrigues M. E., and Henriques M. (2017). Candida species biofilms’ antifungal resistance. J. Fungi. 3, 8. doi: 10.3390/jof3010008
Singampalli A., Bandela R., Kumar P., Bakchi B., Maddipatla S., Bellapukonda S. M., et al. (2025). Exploration of benzofuran/indole-chalcone conjugated 1, 2, 3-triazole hybrids as candida glabrata agents: design, synthesis, biological evaluation, molecular docking, and in silico ADMET analysis. Chem. Biodivers. 22, e202500345. doi: 10.1002/cbdv.202500345
Siswina T., Rustama M. M., Sumiarsa D., and Kurnia D. (2023). Phytochemical profiling of Piper crocatum and its antifungal mechanism action as Lanosterol 14 alpha demethylase CYP51 inhibitor: a review. F1000Research 11, 1115. doi: 10.12688/f1000research.125645.3
Soliman S., Alnajdy D., El-Keblawy A. A., Mosa K. A., Khoder G., and Noreddin A. M. (2017). Plants’ natural products as alternative promising anti-Candida drugs. Pharmacogn. Rev. 11, 104. doi: 10.4103/phrev.phrev_8_17
Soulaimani B., Varoni E., Iriti M., Mezrioui N. E., Hassani L., and Abbad A. (2021). Synergistic anticandidal effects of six essential oils in combination with fluconazole or amphotericin B against four clinically isolated Candida strains. Antibiotics 10, 1049. doi: 10.3390/antibiotics10091049
Stachelska MA, Karpiński P, and Kruszewski B (2025). A comprehensive review of biological properties of flavonoids and their role in the prevention of metabolic, cancer and neurodegenerative diseases. Applied Sciences 15, 10840. doi: 10.3390/app151910840
Sureendar B., Gunasekaran V., Ganapathy D., and Sathishkumar P. (2025). Possible applicability of flavonoid hesperetin for the treatment of dental biofilm-forming Candida glabrata. J. Oral. Biol. Craniofacial. Res. 15, 1799–1805. doi: 10.1016/j.jobcr.2025.10.016
Szweda P., Gucwa K., Kurzyk E., Romanowska E., Dzierżanowska-Fangrat K., Zielińska Jurek A., et al. (2015). Essential oils, silver nanoparticles and propolis as alternative agents against fluconazole resistant Candida albicans, Candida glabrata and Candida krusei clinical isolates. Indian J. Microbiol. 55, 175–183. doi: 10.1007/s12088-014-0508-2
Tan J., Zhang Z., Zheng D., Mu Y., Cao B., Yang J., et al. (2024). Structure–activity relationship and biofilm formation-related gene targets of oleanolic acid-type saponins from Pulsatilla chinensis against Candida albicans. Bioorg. Chem. 146, 107311. doi: 10.1016/j.bioorg.2024.107311
Teodoro G. R., Ellepola K., Seneviratne C. J., and Koga-Ito C. Y. (2015). Potential use of phenolic acids as anti-Candida agents: A review. Front. Microbiol. 6, 1420. doi: 10.3389/fmicb.2015.01420
Thawabteh A. M., Ghanem A. W., AbuMadi S., Thaher D., Jaghama W., Karaman R., et al. (2024). Antibacterial activity and antifungal activity of monomeric alkaloids. Toxins 16, 489. doi: 10.3390/toxins16110489
Timmermans B., De Las Peñas A., Castaño I., and Van Dijck P. (2018). Adhesins in Candida glabrata. J. Fungi. 4 (2), 60. doi: 10.3390/jof4020060
Tits J., Cammue B. P., and Thevissen K. (2020). Combination therapy to treat fungal biofilm-based infections. Int. J. Mol. Sci. 21, 8873. doi: 10.3390/ijms21228873
Tong Y., Zhang J., Sun N., Wang X. M., Wei Q., Zhang Y., et al. (2021). Berberine reverses multidrug resistance in Candida albicans by hijacking the drug efflux pump Mdr1p. Sci. Bull. 66, 1895–1905. doi: 10.1016/j.scib.2020.12.035
Torelli R., Posteraro B., Ferrari S., La Sorda M., Fadda G., Sanglard D., et al. (2008). The ATP-binding cassette transporter–encoding gene CgSNQ2 is contributing to the CgPDR1-dependent azole resistance of Candida glabrata. Mol. Microbiol. 68, 186–201. doi: 10.1111/j.1365-2958.2008.06143.x
Tóth Hervay N., Eliaš D., Černáková L., Jacko J., Habová M., Chovancová N., et al. (2024). Enhancement of ROS production by catechin is a primary effect of increased azole efficacy in nakaseomyces glabratus (Candida glabrata) cells lacking the ERG6 gene. Pathogens 13, 834. doi: 10.3390/pathogens13100834
Tyagi A. K. and Malik A. (2010). Liquid and vapour-phase antifungal activities of selected essential oils against Candida albicans: microscopic observations and chemical characterization of Cymbopogon citratus. BMC Complement. Altern. Med. 10, 65. doi: 10.1186/1472-6882-10-65
Váczi P., Proškovcová M., Čonková E., Marcinčáková D., Bačkorová M., and Harčárová M. (2024). Essential oil and plant extract of oregano as agents influencing the virulence factors of Candida albicans. Pol. J. Vet. Sci. 27, 25–33. doi: 10.24425/pjvs.2024.149330
Vahedi G., Khosravi A. R., Shokri H., Moosavi Z., Delirezh N., Sharifzadeh A., et al. (2016). Fungicidal effect of Origanum vulgare essential oil against Candida glabrata and its cytotoxicity against macrophages. J. HerbMed. Pharmacol. 5, 78–84.
Vandeputte P., Ferrari S., and Coste A. T. (2012). Antifungal resistance and new strategies to control fungal infections. Int. J. Microbiol. 2012, 713687. doi: 10.1155/2012/713687
Vu B. G. and Moye-Rowley W. S. (2022). Azole-resistant alleles of ERG11 in Candida glabrata trigger activation of the Pdr1 and Upc2A transcription factors. Antimicrob. Agents Chemother. 66, e02098–e02021. doi: 10.1128/aac.02098-21
Weisany W., Yousefi S., Tahir N. A. R., Golestanehzadeh N., McClements D. J., Adhikari B., et al. (2022). Targeted delivery and controlled released of essential oils using nanoencapsulation: A review. Adv. Colloid. Interface Sci. 303, 102655. doi: 10.1016/j.cis.2022.102655
Wicaksono S., Rezkita F., Wijaya F. N., Nugraha A. P., and Winias S. (2020). Ellagic acid: an alternative for antifungal drugs resistance in HIV/AIDS patients with oropharyngeal candidiasis. HIV AIDS Rev. Int. J. HIV-Related. Probl. 19, 153–156. doi: 10.5114/hivar.2020.98007
Won E. J., Choi M. J., Kim M. N., Yong D., Lee W. G., Uh Y., et al. (2021). Fluconazole-resistant Candida glabrata bloodstream isolates, South Korea 2008–2018. Emerg. Infect. Dis. 27, 779. doi: 10.3201/eid2703.203482
Yamin D., Wakil A. M., Goni M. D., Irekeola A. A., and Hajissa K. (2025). Trends of Candida species causing bloodstream infections in South-Eastern Asia: A systematic review and meta-analysis. Asian Pac. J. Trop. Med. 18, 51–66. doi: 10.4103/apjtm.apjtm_559_24
Yong J., Zu R., Huang X., Ge Y., and Li Y. (2020). Synergistic effect of berberine hydrochloride and fluconazole against Candida albicans resistant isolates. Front. Microbiol. 11, 1498. doi: 10.3389/fmicb.2020.01498
Zajac C., Scott N. E., Kline S., Erayil S. E., and Selmecki A. (2025). Hotspot gene conversion between FKS1 and FKS2 in echinocandin resistant Candida glabrata serial isolates. NPJ Antimicrob. Res. 3, 31. doi: 10.1038/s44259-025-00102-6
Zheng D., Yue D., Shen J., Li D., Song Z., Huang Y., et al. (2023). Berberine inhibits Candida albicans growth by disrupting mitochondrial function through the reduction of iron absorption. J. Appl. Microbiol. 134, lxad276. doi: 10.1093/jambio/lxad276
Keywords: antifungal resistance, biofilm inhibition, Candida glabrata, natural products, phytochemicals
Citation: Sahu BK, Patra SK, Sahu MC and Panda SK (2026) Natural product based approaches to overcome Candida glabrata and emerging AMR threats. Front. Antibiot. 5:1767032. doi: 10.3389/frabi.2026.1767032
Received: 13 December 2025; Accepted: 20 January 2026; Revised: 15 January 2026;
Published: 10 February 2026.
Edited by:
Pablo Mendez-Pfeiffer, University of Sonora, MexicoCopyright © 2026 Sahu, Patra, Sahu and Panda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sujogya Kumar Panda, c3Vqb2d5YXBhbmRhQHNvYS5hYy5pbg==